Selection of Treatment Regimens for Recurrent Cervical Cancer
ObjectiveThe selection of individualized treatment for recurrent cervical cancer is challenging. This study aimed to investigate the impact of various therapies on survival outcomes after recurrence.MethodsEligible patients were diagnosed with recurrent cervical cancer between March 2012 and April 2...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.618485/full |
| _version_ | 1819174034999345152 |
|---|---|
| author | Xiaopei Chao Xiaochen Song Huanwen Wu Yan You Ming Wu Lei Li |
| author_facet | Xiaopei Chao Xiaochen Song Huanwen Wu Yan You Ming Wu Lei Li |
| author_sort | Xiaopei Chao |
| collection | DOAJ |
| description | ObjectiveThe selection of individualized treatment for recurrent cervical cancer is challenging. This study aimed to investigate the impact of various therapies on survival outcomes after recurrence.MethodsEligible patients were diagnosed with recurrent cervical cancer between March 2012 and April 2018. Postrecurrence progression-free survival (PFS) and overall survival (OS) were investigated in the whole cohort and in subgroups, categorized by recurrence site and prior radiotherapy history, using a multivariate model that incorporated treatment for primary and recurrent tumors, histological pathology, and FIGO staging.ResultsTwo hundred and sixty recurrent cervical cancer patients were included. As of March 1, 2020, the median postrecurrence PFS and OS were 7.0 (range 0-94) and 24.0 (1.8-149.1) months, respectively. In a multivariate model measured by PFS, radiotherapy was superior to other therapies for the whole cohort (p=0.029) and recurrence only within the pelvic cavity (p=0.005), but the advantages of radiotherapy disappeared in patients with a history of radiotherapy (p values >0.05). For recurrence only beyond the pelvic cavity, combination therapy resulted in improved PFS (p=0.028). For recurrence both within and beyond the pelvic cavity, no therapy regimen provided additional PFS benefits (p values >0.05). Radiotherapy and combination therapy were also associated with improved postrecurrence OS for recurrence within the pelvic cavity (p=0.034) and only beyond the pelvic cavity (p=0.017), respectively.ConclusionsIn cervical cancer patients, postrecurrence radiotherapy can improve PFS and OS for patients with recurrence within the pelvic cavity and without prior radiotherapy. For recurrence beyond the pelvic cavity or cases with a history of radiotherapy, combination or individualized therapy may provide potential survival benefits. |
| first_indexed | 2024-12-22T20:32:34Z |
| format | Article |
| id | doaj.art-e24aa42068a34970b0330ee1fa2657e7 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T20:32:34Z |
| publishDate | 2021-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e24aa42068a34970b0330ee1fa2657e72022-12-21T18:13:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-02-011110.3389/fonc.2021.618485618485Selection of Treatment Regimens for Recurrent Cervical CancerXiaopei Chao0Xiaochen Song1Huanwen Wu2Yan You3Ming Wu4Lei Li5Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, ChinaDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, ChinaDepartment of Pathology, Peking Union Medical College Hospital, Beijing, ChinaDepartment of Pathology, Peking Union Medical College Hospital, Beijing, ChinaDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, ChinaDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, ChinaObjectiveThe selection of individualized treatment for recurrent cervical cancer is challenging. This study aimed to investigate the impact of various therapies on survival outcomes after recurrence.MethodsEligible patients were diagnosed with recurrent cervical cancer between March 2012 and April 2018. Postrecurrence progression-free survival (PFS) and overall survival (OS) were investigated in the whole cohort and in subgroups, categorized by recurrence site and prior radiotherapy history, using a multivariate model that incorporated treatment for primary and recurrent tumors, histological pathology, and FIGO staging.ResultsTwo hundred and sixty recurrent cervical cancer patients were included. As of March 1, 2020, the median postrecurrence PFS and OS were 7.0 (range 0-94) and 24.0 (1.8-149.1) months, respectively. In a multivariate model measured by PFS, radiotherapy was superior to other therapies for the whole cohort (p=0.029) and recurrence only within the pelvic cavity (p=0.005), but the advantages of radiotherapy disappeared in patients with a history of radiotherapy (p values >0.05). For recurrence only beyond the pelvic cavity, combination therapy resulted in improved PFS (p=0.028). For recurrence both within and beyond the pelvic cavity, no therapy regimen provided additional PFS benefits (p values >0.05). Radiotherapy and combination therapy were also associated with improved postrecurrence OS for recurrence within the pelvic cavity (p=0.034) and only beyond the pelvic cavity (p=0.017), respectively.ConclusionsIn cervical cancer patients, postrecurrence radiotherapy can improve PFS and OS for patients with recurrence within the pelvic cavity and without prior radiotherapy. For recurrence beyond the pelvic cavity or cases with a history of radiotherapy, combination or individualized therapy may provide potential survival benefits.https://www.frontiersin.org/articles/10.3389/fonc.2021.618485/fullcervical cancerrecurrenceradiotherapychemotherapysurgeryprogression-free survival |
| spellingShingle | Xiaopei Chao Xiaochen Song Huanwen Wu Yan You Ming Wu Lei Li Selection of Treatment Regimens for Recurrent Cervical Cancer Frontiers in Oncology cervical cancer recurrence radiotherapy chemotherapy surgery progression-free survival |
| title | Selection of Treatment Regimens for Recurrent Cervical Cancer |
| title_full | Selection of Treatment Regimens for Recurrent Cervical Cancer |
| title_fullStr | Selection of Treatment Regimens for Recurrent Cervical Cancer |
| title_full_unstemmed | Selection of Treatment Regimens for Recurrent Cervical Cancer |
| title_short | Selection of Treatment Regimens for Recurrent Cervical Cancer |
| title_sort | selection of treatment regimens for recurrent cervical cancer |
| topic | cervical cancer recurrence radiotherapy chemotherapy surgery progression-free survival |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.618485/full |
| work_keys_str_mv | AT xiaopeichao selectionoftreatmentregimensforrecurrentcervicalcancer AT xiaochensong selectionoftreatmentregimensforrecurrentcervicalcancer AT huanwenwu selectionoftreatmentregimensforrecurrentcervicalcancer AT yanyou selectionoftreatmentregimensforrecurrentcervicalcancer AT mingwu selectionoftreatmentregimensforrecurrentcervicalcancer AT leili selectionoftreatmentregimensforrecurrentcervicalcancer |